Health Law Professor & Institute for Public Health Faculty Scholar, Rachel Sachs discusses the role of state boards on drug affordability and what their decisions can mean for the public.
Tag: Rachel Sachs
CMS to work closely with FDA on accelerated approval payment reforms (Links to an external site)
Law Professor and Institute Faculty Scholar, Rachel Sachs discusses a change in reimbursement to providers as CMS-the Centers for Medicare & Medicaid Services-works with the FDA to accelerate payment reforms.
Lawmakers are readying fresh attacks on pharmacy middlemen (Links to an external site)
Faculty Scholar and professor at the School of Law, Rachel Sachs discusses “PBM reform”.
Broken promises? FDA needs more power to remove drugs from marketplace, JAMA analysis finds (Links to an external site)
Faculty Scholar, Rachel Sachs discusses data from drug extension trials, which did not show substantial effectiveness.
Get ready for a drug importation revival (Links to an external site)
Law professor and Institute Faculty Scholar, Rachel Sachs, JD, speaks about drug importation and how it is not currently used for lowering prices.
Drugmakers seek prolonged shield from Medicare price negotiation (Links to an external site)
The Inflation Reduction Act allows Medicare for the first time to negotiate with drug manufacturers for lower prices. Faculty Scholar, Rachel Sachs weighs in.
Val Demings criticizes Rubio’s move to repeal law’s drug provisions (Links to an external site)
Faculty Scholar and law professor Rachel Sachs discusses the latest changes to Medicare’s system of paying for prescription drugs.
Medicare rejected a controversial Alzhiemer’s drug. Participants still ended up paying for it. (Links to an external site)
Because there is currently no way to change prescription premiums mid-year and save people money, law professor and Faculty Scholar, Rachel Sachs says, the high costs of drugs rejected by Medicare are unfortunately passed on to consumers.
Congress moves forward with “clean” deal to fund FDA (Links to an external site)
Health law expert and Faculty Scholar Rachel Sachs discusses a new deal in congress that would fund the FDA.
EXPLAINER: Lower prescription prices take time in new law (Links to an external site)
Rachel Sachs JD, MPH, institute Faculty Scholar and Treiman Professor of Law at the School of Law, explains some of the cost-cutting provisions in the Inflation Reduction Act specific to Medicare in this AP article.
Drug Negotiations Will Drive Biosimilars as Patent Tactics Shift (Links to an external site)
Check out this Bloomberg Law article featuring Rachel Sachs JD, MPH, institute Faculty Scholar, who discusses how pharmaceutical companies may begin to encourage biosimilar products to come to market to avoid negotiating drug prices with Medicare.
New drug pricing law puts cancer drugs in spotlight (Links to an external site)
Institute Faculty Scholar, Rachel Sachs JD, MPH, speaks with Axios about how recent legislation, that enables Medicare to negotiate drug prices with pharmaceutical companies, may impact the development of cancer treatments.
Fact-Checking Health Claims About the Inflation Reduction Act (Links to an external site)
Check out this New York Times article featuring Institute Faculty Scholar and Treiman Professor of Law at the School of Law, Rachel Sachs JD, MPH, who discusses some misunderstandings surrounding the Inflation Reduction Act.
Medicare chief vows to implement drug pricing reforms on time (Links to an external site)
Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs JD, MPH, discusses the recent Inflation Reduction Act that will ultimately enable Medicare to negotiate drug prices with the pharmaceutical industry.
Since Biden took over, Big Pharma has spent $205 million to protect drug price status quo, analysis finds (Links to an external site)
Rachel Sachs JD, MPH, institute Faculty Scholar and Treiman Professor of Law at the School of Law, speaks with Fierce Pharma about the pharmaceutical industry’s response to the Biden administration, specifically the recent Inflation Reduction Act.
How Medicare drug costs could change under the Inflation Reduction Act (Links to an external site)
Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs JD, MPH, discusses the impact of a new bill that allows Medicare to negotiate drug prices for a select number of expensive drugs.
HEALTH CARE BRIEFING: Drug Bill Shows Limits of Democrat’s Power (Links to an external site)
Rachel Sachs JD, MPH, institute faculty scholar and Treiman Professor of Law at the School of Law, discusses recent federal legislation that enables Medicare to negotiate the prices of some of the most expensive pharmaceuticals
Major drug price reforms head for Biden’s signature as PhRMA weighs legal options (Links to an external site)
Institute Faculty Scholar and Treiman Professor of Law at the School of Law, Rachel Sachs JD, MPH, discusses with EndpointNews possible legal avenues for PhRMA following recent federal legislation
Dems’ Medicare win faces long, uncertain future (Links to an external site)
Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs discusses the new bill that would allow Medicare to negotiate drug prices for a select number of expensive drugs.
Drug industry on verge of rare defeat (Links to an external site)
Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs discusses the new bill that would allow Medicare to negotiate drug prices for a select number of expensive drugs
Drug industry poised for rare political loss on prices (Links to an external site)
Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs discusses the new Senate bill that would allow Medicare to negotiate drug prices for a select number of very expensive drugs in this Washington Post article.
Ad Targeting Manchin and AARP Mischaracterizes Medicare Drug-Price Negotiations (Links to an external site)
Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs, weighs in on the validity of an ad targeting Senator Joe Manchin and AARP, characterizing it as “fairly misleading”
People with chronic illness in US now having medication restricted (Links to an external site)
Rachel Sachs, institute faculty scholar and Treiman Professor of Law at the School of Law, discusses with Bloomberg the potential for restrictions on medications in Missouri following the Supreme Court’s overturning of Roe v. Wade.